AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
CGC   19.90 (-0.55%)
BABA   201.18 (-0.27%)
MU   49.45 (+7.97%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
F   6.03 (+3.25%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
NFLX   419.89 (+1.23%)
BAC   25.98 (+7.00%)
BA   149.52 (+3.31%)
Log in

ASX:MEBMedibio Stock Price, Forecast & News

0.0070
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.01
Now: A$0.01
A$0.01
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range
A$0.01
Now: A$0.01
A$0.03
Volume1.26 million shs
Average VolumeN/A
Market Capitalization$6.97 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medibio Limited, a health technology company, engages in the development of diagnostic systems for mental health illnesses in Australia and the United States. It is involved in the research, development, and commercialization of mental health technology using objective biomarkers to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions. Medibio Limited has a research agreement with the Department of Biomedical Sciences of Humanitas University for the development of mental health software products. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was founded in 1998 and is headquartered in Savage, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.53 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone952-222-0551

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.47 million
Cash FlowA$0.00 per share
Book ValueA$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$6.97 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MEB News and Ratings via Email

Sign-up to receive the latest news and ratings for MEB and its competitors with MarketBeat's FREE daily newsletter.

Medibio (ASX:MEB) Frequently Asked Questions

How has Medibio's stock been impacted by COVID-19 (Coronavirus)?

Medibio's stock was trading at A$0.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEB stock has increased by 0.0% and is now trading at A$0.01. View which stocks have been most impacted by Coronavirus.

Has Medibio been receiving favorable news coverage?

News coverage about MEB stock has trended negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medibio earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMedibio.

Who are some of Medibio's key competitors?

Who are Medibio's key executives?

Medibio's management team includes the following people:
  • Mr. David B. Kaysen, Chairman, CEO & MD (Age 69)
  • Ms. Melanie Jaye Leydin C.A., B.Bus, CA, Joint Company Sec. & Director (Age 46)
  • Ms. Peggy Morgan, Corp. Controller
  • Ms. Stephanie Ottens, Investor Relations Director
  • Mr. Josh Purdy, PR Director

What is Medibio's stock symbol?

Medibio trades on the ASX under the ticker symbol "MEB."

What is Medibio's stock price today?

One share of MEB stock can currently be purchased for approximately A$0.01.

How big of a company is Medibio?

Medibio has a market capitalization of $6.97 million and generates $1.47 million in revenue each year.

What is Medibio's official website?

The official website for Medibio is www.medibio.com.au.

How can I contact Medibio?

The company can be reached via phone at 952-222-0551.

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.